Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07516379 · ClinicalTrials.gov registry record

GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation

A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Recruiting
Registry status
100
Enrollment target

NCT07516379 is a clinical trial that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07516379 is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

RECRUITING
Registry status
100 participants
Enrollment target

Study Summary

Background: Lung transplants can save lives, but the procedure has risks. Some people develop donor-specific antibodies (DSA) after the procedure-that is, their bodies create proteins that treat the new lungs as foreign and mount an immune response against them. This is called rejection. But not everyone who has a transplant develops DSA, and not everyone who has DSA develops rejection. Researchers want to understand why. Objective: To collect data to try to find out why some people develop rejection after lung transplants while others do not. Eligibility: People aged 18 to 75 years who have progressive lung disease or undergone or may undergo a lung transplant. Design: Participants will have clinic visits every 3 to 6 months for up to 4 years. Some visits might require an overnight stay. Each visit will include multiple tests and procedures: Physical exam with blood and urine tests. Some blood will be used for genetic testing. Imaging scans. Participants will have 2 types of scan to get images of their lungs. For one, they will have a contrast agent given through a tube inserted into a vein. Six-minute walk test. Participants will walk back and forth in a hallway at their own pace. Researchers will check on how their body responds. Lung function test. Participants will breathe into a tube connected to a machine. Two other tests are optional: Bronchoscopy with washings (lavage). A long tube with a light will be threaded down through the participant s nose or mouth and into their lungs. Endomicroscopy. During the bronchoscopy a tiny camera may be used to take pictures inside the lungs. ...

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2026-05-11
Est. Completion 2032-03-27

What the Registry Record Tells You About NCT07516379

The ClinicalTrials.gov registry entry for NCT07516379 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT07516379 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07516379 about?

NCT07516379 is a clinical study titled "GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation". Background: Lung transplants can save lives, but the procedure has risks. Some people develop donor-specific antibodies (DSA) after the procedure-that is, their bodies create proteins that treat the new lungs as foreign and mount an immune response against them. This is called rejection. But not ev...

What is the current status of trial NCT07516379?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2026-05-11. Estimated completion is 2032-03-27.

Who is sponsoring clinical trial NCT07516379?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.